#1 Clinical Trials Search in Europe

Specific Nucleic Acid Sna-Papi

The PAPION study is a randomized, placebo-controlled, double-blind clinical trial investigating the effectiveness of 2LPAPI®, a drug containing Specific Nucleic Acid SNA-PAPI, in clearing high-risk human papillomavirus (HR-HPV) genital infections. This Phase IV trial aims to compare the efficacy of 2LPAPI® against a placebo over a 12-month period, focusing on women aged 25-45 with HR-HPV diagnoses.

Table of Contents

What is 2LPAPI?

2LPAPI is a new medication being studied for the treatment of genital HPV infections. It comes in the form of granules in capsules that are meant to be opened before use[1]. The medication contains several active ingredients, including a substance called SPECIFIC NUCLEIC ACID SNA-PAPI, which is specifically designed to target the human papillomavirus (HPV)[1].

This medication is also known by other names, including:

  • SNA-PAPI
  • SPECIFIC NUCLEIC ACID – HUMAN PAPILLOMAVIRUS

Medical Conditions Treated

2LPAPI is being studied for the treatment of Human Papillomavirus (HPV) infections, specifically focusing on genital infections caused by high-risk HPV types[1]. HPV is a common virus that can lead to various health issues, including:

  • Genital warts: These are growths that appear on the genitals or surrounding areas.
  • Cervical abnormalities: HPV can cause changes in the cells of the cervix, which may lead to cervical cancer if left untreated.
  • Other reproductive system disorders: HPV can affect both the male and female reproductive systems[1].

How 2LPAPI Works

2LPAPI contains a combination of ingredients that work together to target HPV infections[1]. Some of the key components include:

  • Interferon alfa: A protein that helps boost the immune system’s response to viral infections.
  • Interleukin-1 and Interleukin-2: These are also proteins that play a role in immune system function.
  • Specific Nucleic Acid SNA-PAPI: This is a specially designed substance that targets the HPV virus.
  • Ribonucleic acid (RNA): A type of genetic material that may help in fighting the virus.

These ingredients work together to help the body’s immune system recognize and fight off the HPV infection more effectively[1].

Clinical Trial Details

A clinical trial called the PAPION study is currently being conducted to evaluate the effectiveness of 2LPAPI in treating genital HPV infections[1]. Here are some key details about the trial:

  • It is a Phase IV clinical trial, which means the medication has already been approved for use but is being studied further to gather more information about its effectiveness and safety.
  • The study is randomized, placebo-controlled, and double-blind. This means that participants are randomly assigned to receive either 2LPAPI or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study.
  • The main goal is to compare the effectiveness of 2LPAPI versus a placebo in clearing genital high-risk HPV infections after 12 months of treatment[1].

Eligibility Criteria

The clinical trial has specific criteria for who can participate. Some of the main requirements include[1]:

  • Women between 25 and 45 years old
  • Current diagnosis of a high-risk HPV infection
  • Normal or mildly abnormal cervical cytology results (no more than LSIL or CIN I)
  • In a stable sexual relationship
  • Not pregnant or breastfeeding
  • No severe immune system deficiencies

There are additional criteria that the study doctors use to determine eligibility, so it’s important to consult with a healthcare provider if you’re interested in participating[1].

Potential Benefits

The study aims to determine if 2LPAPI can provide the following benefits[1]:

  • Clearance of high-risk HPV infections
  • Improvement in cervical cytology results
  • Normalization of cervical cells in patients with initially abnormal results

It’s important to note that these potential benefits are still being studied, and the effectiveness of the treatment is not yet fully known[1].

Safety Considerations

As with any medication, there are potential risks and side effects to consider. The clinical trial is monitoring for[1]:

  • Adverse events (AEs): These are any undesirable experiences associated with the use of the medication.
  • Serious adverse events (SAEs): These are more severe or life-threatening side effects.

The study will track both events related to the medication and those unrelated to it. It’s crucial to discuss potential risks and benefits with a healthcare provider before considering any new treatment[1].

Aspect Details
Study Name PAPION Study
Drug Tested 2LPAPI®
Main Active Ingredient Specific Nucleic Acid SNA-PAPI
Study Design Randomized, placebo-controlled, double-blind
Primary Objective Evaluate efficacy in clearing HR-HPV genital infections
Study Duration 12 months
Participant Age Range 25-45 years old
Key Inclusion Criteria HR-HPV diagnosis, normal or low-grade cytology
Primary Endpoint HR-HPV infection clearance at 12 months
Secondary Endpoints Clearance at 6 months, by HPV type, cytology changes, safety

FAQ

  • What is the main goal of the PAPION study? The main goal of the PAPION study is to compare the effectiveness of 2LPAPI® versus a placebo in clearing high-risk HPV genital infections after 12 months of treatment.
  • Who can participate in this clinical trial? Women between 25 and 45 years old with a current HR-HPV diagnosis, normal or low-grade cervical cytology results, and in a stable sexual relationship can participate. They must also be able to use effective contraception throughout the study.
  • What does the treatment involve? The treatment involves taking 2LPAPI®, which comes in the form of granules in capsules that are to be opened. Participants will either receive the active drug or a placebo, and the study will last for 12 months.
  • What are the main outcomes being measured? The primary outcome is HR-HPV infection clearance at the 12-month visit. Secondary outcomes include clearance at 6 months, clearance by HPV type, changes in cervical cytology, and safety assessments.
  • Are there any specific exclusion criteria? Yes, some exclusion criteria include pregnancy, breastfeeding, recent HPV vaccination, severe immune deficiency, use of certain homeopathic or phytotherapy treatments, and addiction to recreational drugs.

Ongoing Clinical Trials on Specific Nucleic Acid Sna-Papi

  • Study on the Effectiveness of 2LPAPI with Interferon Alfa in Clearing Genital HPV Infections in Patients

    Recruiting

    3 1 1
    Investigated drugs:
    Belgium Romania

Glossary

  • HPV (Human Papillomavirus): A common virus that can cause infections in the genital area, some of which may lead to cancer.
  • HR-HPV (High-Risk HPV): Specific types of HPV that are more likely to cause cancer or precancerous lesions.
  • Cytology: The study of cells under a microscope, often used to detect abnormal cells in cervical screening tests.
  • LSIL (Low-grade Squamous Intraepithelial Lesion): A mild abnormality in cervical cells that may be caused by HPV infection.
  • CIN (Cervical Intraepithelial Neoplasia): Abnormal changes in the cells on the surface of the cervix, graded from I (mild) to III (severe).
  • ASC-US (Atypical Squamous Cells of Undetermined Significance): A cervical cytology result indicating slight cell abnormalities that are not clearly precancerous.
  • AGUS (Atypical Glandular Cells of Undetermined Significance): Abnormal glandular cells found in a cervical cytology test, which may require further investigation.
  • ASC-H (Atypical Squamous Cells, cannot exclude HSIL): A cytology result suggesting possible high-grade squamous lesions that require further evaluation.
  • AGC (Atypical Glandular Cells): Abnormal glandular cells found in a cervical cytology test that may indicate a higher risk of cervical cancer.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a new treatment against no treatment.
  • Double-blind study: A research design where neither the participants nor the researchers know who is receiving the actual treatment or placebo.
  • Specific Nucleic Acid SNA-PAPI: An active ingredient in 2LPAPI® designed to target HPV-related infections.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-2lpapi-with-interferon-alfa-in-clearing-genital-hpv-infections-in-patients/